Six-year follow-up of a cohort of 203 patients with diabetes after screening for silent myocardial ischaemia

Diabetic Medicine

Volumn 23, Issue 11, 2006, Pages 1186-1191

  Sejil, S ^a,b   Janand Delenne, B ^a   Avierinos, J F ^a   Habib, G ^a   Labastie, N ^a   Raccah, D ^a   Vague, P ^a   Lassmann Vague, V ^a  

^a TIMONE HOSPITAL   (France)

^b CENTRE HOSPITALIER DU PAYS D AIX   (France)

Author keywords

Adult diabetes; Cancer; Cardiovascular disease; Mortality; Silent myocardial ischaemia

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BODY MASS; CANCER; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SILENT MYOCARDIAL ISCHEMIA; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 33750187154     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01992.x     Document Type: Article

References (40)

1. Passa P, Drouin P, Issa-Sayeg M, Blasco A, Masquet C, Monassier JP et al. Coronary disease and diabetes. Diabetes Metabolism 1995; 21: 446-451.
2. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes, 10-11 February 1998, Miami, Florida. Diabetes Care 1998; 21: 1551-1559.
3. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI. Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-2239.
4. Puel J, Valensi P, Vanzetto G, Lassmann-Vague V, Monin JL, Moulin P et al. on behalf of ALFEDIAM and SFC. Identification of myocardial ischemia in diabetic patient. Joint ALFEDIAM and SFC recommendations. Diabetes Metab 2004; 30: 3S3-18.
5. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol 2002; 90: 827-832.
6. Elhendy A, Domburg RT, Poldermans D, Bax JJ, Nierop PR, Geleijnse ML et al. Safety and feasibility of dobutamine-atropine stress echography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test. Diabetes Care 1998; 21: 1797-1802.
7. Sozzi FB, Elhendy A, Roelandt JRTC, Domburg RT, Schinkel AFL, Vourvouri EC et al. Prognostic value of dobutamine stress echography in patients with diabetes. Diabetes Care 2003; 26: 1074-1078.
8. Valensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Cosson E et al. Predictive value of cardiac autonomic neuropathiy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001; 24: 339-343.
9. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes: Who to screen. Diabetes Care 1999; 22: 1396-1400.
10. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
11. Faglia E, Favales F, Calia P, Paleari F, Segalini G, Gamba PL et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care 2002; 25: 2032-2036.
12. Zellweger MJ, Hachamovitch R, Kang X, Hayes SW, Friedman JD, Germano G et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Eur Heart J 2004; 25: 543-550.
13. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care 2003; 26: 1313-1314.
14. Vanzetto G, Halimi S, Hammoud T, Fagret D, Benhamou PY, Cordonnier D et al. Pronostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care 1999; 22: 19-26.
15. Nesto RW, Phillips RT, Kett KG, Hill T, Perper E, Young E et al. Angina and exertional myocardial ischemia in diabetic and non diabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988; 108: 170-175.
16. Grundy SM, Benjamin IL, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
17. Gu K, Cowie CC, Harris IM. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-93. Diabetes Care 1998; 21: 1138-1145.
18. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 1101-1107.
19. Redberg RF, Greenland P, Fuster V, Pyorala K, Blair SN, Folsom AR et al. Prevention Conference VI. Diabetes and Cardiovascular Disease: Writing Group III. Risk assessment in persons with diabetes. Circulation 2002; 105: e144-152.
20. US Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. Ann Intern Med 2004; 140: 569-572.
21. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S; HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339-1346.
22. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of anti-platelet therapy. I. Prevention of death, myocardial infarction and stoke by prolonged anti-platelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
23. Hippisley-Cox J, Coupland C. The effect of statins on the mortality of patients with ischaemic heart disease: population-based cohort study with nested case-control analysis. Heart 2006; 92: 752-758.
24. Beishuizen ED, Jukema JW, Tamsma JT, Van De Ree MA, Van Der Vijver JC et al. No effect of statin therapy on silent myocardial ischemia in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005; 28: 1675-1679.
25. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
26. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willet WC, Speizer FE et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001; 161: 1717-1723.
27. Berglund G, Nilsson P, Eriksson KF, Hedblad B, Kristenson H, Lindgarde F. Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity. J Intern Med 2000; 247: 19-29.
28. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?. Diabetes Metab 2003; 29: 470-476.
29. Nanchahal K, Morris JN, Sullivan LM, Wilson PW. Coronary heart disease risk in men and the epidemic of overweight and obesity. Int J Obes Relat Metab Disord 2005; 29: 317-323.
30. Viswanathan V, Snehalatha C, Mathai T, Jayaraman M, Ramachandran A. Cardiovascular morbidity in proteinuric South India NIDDM patients. Diabetes Res Clin Prac 1998; 39: 63-67.
31. Fredenrich A, Castillo-Ros S, Hieronimus S, Baudony M, Harter M, Canivet B. Screening for silent myocardial ischemia in diabetic patients. Diabetes Care 2000; 23: 563-564.
32. 1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
33. Fox SC, Sullivan L, D'Agostino RB, Wilson PWF. The significant effect of diabetes duration on coronary heart disease mortality. The Framingham Heart Study. Diabetes Care 2004; 27: 704-708.
34. Eyre H, Kahn R, Robertson RM. for the ACS/ADA/AHA Collaborative Writing Committee. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. CA Cancer J Clin 2004; 54: 190-207.
35. Minino AM, Smith BL. Deaths. Preliminary Data for 2000. National Vital Statistics Reports. Vol. 49, no. 12. Hyattsville, MD: National Center for Health Statistics, 2001.
36. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004; 33: 189-198.
37. Su J, Tian H, Li CL, Wang Y. Analysis of the cause of hospital death in aged diabetics. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 110-112.
38. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patient with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
39. Scheen AJ, Radermecker RP, Philips JC. Effects of intensive insulin therapy after an acute myocardial infarction in patients with type 2 diabetes: results of the DIGAMI-2 trial. Rev Med Liege 2004; 59: 534-539.
40. Weiner DA, Ryan TJ, Fisher LD, Chaitman BR, Sheffield LT, Tristani FE. Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus: a report from the Coronary Artery Surgery Study (CASS) registry. Am J Cardiol 1991; 68: 729-734.